Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
14 hedge funds and large institutions have $1.38M invested in Evoke Pharma in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
56% more funds holding
Funds holding: 9 → 14 (+5)
8% less capital invested
Capital invested by funds: $1.49M → $1.38M (-$112K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
+$88K |
| 2 |
Bank of New York Mellon
New York
|
+$81.8K |
| 3 |
Millennium Management
New York
|
+$35.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$16.3K |
| 5 |
Walleye Trading
New York
|
+$5.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$459K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$54.4K |
| 3 |
Renaissance Technologies
New York
|
-$38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $429K | -$459K | -903 | -50% |
|
|
2
Millennium Management
New York
| $202K | +$35.1K | +69 | +19% |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $195K | – | – | – |
|
|
KCM
4
Knoll Capital Management
Miami,
Florida
| $184K | – | – | – |
|
5
California Public Employees Retirement System
Sacramento,
California
| $121K | – | – | – |
|
|
ARTA
6
A.R.T. Advisors
New York
| $82K | +$88K | +173 | New |
|
|
7
Bank of New York Mellon
New York
| $77K | +$81.8K | +161 | New |
|
8
Geode Capital Management
Boston,
Massachusetts
| $52K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $15K | +$16.3K | +32 | New |
|
|
10
Bank of America
Charlotte,
North Carolina
| $9K | -$54.4K | -107 | -84% |
|
|
11
Walleye Trading
New York
| $5K | +$5.08K | +10 | New |
|
12
UBS Group
Zurich,
Switzerland
| $4K | +$4.58K | +9 | New |
|
|
BIM
13
BlackRock Investment Management
Wilmington,
Delaware
| $2K | – | – | – |
|
|
BFA
14
BlackRock Fund Advisors
San Francisco,
California
| $2K | +$2.54K | +5 | New |
|
|
15
Renaissance Technologies
New York
| – | -$38K | -92 | Closed |
|
EVOK Hedge Fund Activity: Q4 2015 in Review
14 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2015, worth a combined $1.38M — down 7.5% from $1.49M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EVOK positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $88K. The largest seller was Opaleye Management, cutting an estimated $459K.
- 14 institutional investors held Evoke Pharma (EVOK) as of Q4 2015, up from 9 in Q3 2015.
- Funds reported $1.38M of Evoke Pharma stock for Q4 2015, down 7.5% quarter-over-quarter.
- 6 funds opened new Evoke Pharma positions in Q4 2015 and 1 closed out, a net change of +5 holders.
- The largest Evoke Pharma buyer in Q4 2015 was A.R.T. Advisors, an estimated $88K added.
- The largest Evoke Pharma seller in Q4 2015 was Opaleye Management, an estimated $459K sold.
Based on aggregated 13F filings for Q4 2015.